• / Free eNewsletters & Magazine
  • / My Account
Home>Drug Companies

Drug Companies

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. GlaxoSmithKline Global Pharmaceuticals President Abbas Hussain to Leave -- Update

    GlaxoSmithKline Global Pharmaceuticals President Abbas Hussain to Leave -- Update

  2. Synergy Pharmaceuticals ’ TRULANCE™ (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation

    Synergy Pharmaceuticals ’ TRULANCE™ (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation

  3. COLUCID PHARMACEUTICALS , INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by Eli Lilly and Company May be Unfair to Shareholders

    COLUCID PHARMACEUTICALS , INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by Eli Lilly and Company May be Unfair to Shareholders

  4. Morganti Legal Announces Shareholder Investigation of Endo International plc

    Morganti Legal Announces Shareholder Investigation of Endo International plc

  5. GPM Reminds Investors of the January 3 Deadline in the Class Action Lawsuit Against Allergan PLC

    GPM Reminds Investors of the January 3 Deadline in the Class Action Lawsuit Against Allergan PLC

  6. January 6 Deadline Alert: Law Offices of Howard G. Smith Reminds Endo International plc Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

    January 6 Deadline Alert: Law Offices of Howard G. Smith Reminds Endo International plc Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

  7. GPM Reminds Investors of the January 6th Deadline in the Class Action Lawsuit Against Endo International plc and Encourages Investors to Contact the Firm

    GPM Reminds Investors of the January 6th Deadline in the Class Action Lawsuit Against Endo International plc and Encourages Investors to Contact the Firm

  8. UPDATE: There is a better way to fix our broken 'free market' for drugs than negotiating prices

    UPDATE: There is a better way to fix our broken 'free market' for drugs than negotiating prices

  9. UPDATE: There is a better way to fix our broken 'free market' for drugs than negotiating prices

    UPDATE: There is a better way to fix our broken 'free market' for drugs than negotiating prices

  10. Digital Pathology Market - Forecasts from 2017 to 2022: Market is projected to reach US$931.599 million in 2022, increasing from US$440.810 million in 2016 - Research and Markets

    Digital Pathology Market - Forecasts from 2017 to 2022: Market is projected to reach US$931.599 million in 2022, increasing from US$440.810 million in 2016 - Research and Markets

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.